-
Product Insights
Stress Urinary Incontinence – Drugs In Development, 2023
Global Markets Direct’s, ‘Stress Urinary Incontinence - Drugs In Development, 2023’, provides an overview of the Stress Urinary Incontinence pipeline landscape. The report provides comprehensive information on the therapeutics under development for Stress Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Urinary Incontinence – Drugs In Development, 2023
Global Markets Direct’s, ‘Urinary Incontinence - Drugs In Development, 2023’, provides an overview of the Urinary Incontinence pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gebasaxturev in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gebasaxturev in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gebasaxturev in Metastatic Melanoma Drug Details: Cavatak (Coxsackievirus A21, CVA-21) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cell Therapy for Urinary Stress Incontinence
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Cell Therapy for Urinary Stress Incontinence Drug Details Cell therapy is under development for...
-
Product Insights
Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents, or it may just cause minor leakage. Symptoms include stress incontinence, rashes, and other skin disorders. Risk factors include age, gender, overweight, smoking, and other kidney diseases. Treatment includes anticholinergics and topical estrogen. The Urinary Incontinence drugs in development market research report provide comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis...